136 related articles for article (PubMed ID: 9850444)
21. Generic cyclosporine formulations: more open questions than answers.
Cattaneo D; Perico N; Remuzzi G
Transpl Int; 2005 Apr; 18(4):371-8. PubMed ID: 15773953
[TBL] [Abstract][Full Text] [Related]
22. Conversion from Sandimmune to Neoral in organ transplant recipients.
Bartucci MR; Bayer L; Brooks BK; Chandler L; Himes V; Meiergerd D; Newby B; Satmary NT; Shieck V
J Transpl Coord; 1998 Dec; 8(4):227-33; quiz 234-5. PubMed ID: 10205463
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients.
Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A
Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group.
Pollak R; Wong RL; Chang CT
Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829
[TBL] [Abstract][Full Text] [Related]
25. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group.
Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ
Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231
[No Abstract] [Full Text] [Related]
26. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
27. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
[No Abstract] [Full Text] [Related]
28. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
Qazi YA; Forrest A; Tornatore K; Venuto RC
Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
30. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
[No Abstract] [Full Text] [Related]
31. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
32. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
[No Abstract] [Full Text] [Related]
33. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
34. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.
Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N
J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795
[TBL] [Abstract][Full Text] [Related]
35. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients.
Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood PR
Clin Transplant; 1998 Dec; 12(6):588-92. PubMed ID: 9850457
[TBL] [Abstract][Full Text] [Related]
37. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
[No Abstract] [Full Text] [Related]
38. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
Warrens AN; Salama A; Waters JB; Lechler RI
Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
[No Abstract] [Full Text] [Related]
40. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
